LSC remains closed to the public until further notice, but our mission is more urgent than ever. Click here to make a donation.
JANET L. DENLINGER, PHD
President, Matrix Biology Institute;
Co-Founder and Chief Scientific Officer, Hylaco, LLC
The Matrix Biology Institute (MBI) is a nonprofit research and development organization dedicated to hyaluronan (HA, hyaluronic acid) research and education. Hylaco LLC develops skin care products using specially engineered forms of hyaluronan developed at MBI, and has also started an associated foundation, the Alliance in Reconstructive Surgery (AiRS), to provide funds and accurate information for women whose insurance is not sufficient to cover the costs of reconstructive surgery following mastectomy. Dr. Denlinger is a Founding Board Member of AiRS.
She was cofounder of Biomatrix, Inc., a biotechnology research,development and manufacturing company in New Jersey, where she was Executive Vice President, from 1989 until 2000. Biomatrix, Inc. developed cross-linked hyaluronan derivatives (hylans) for medical applications and for skin care, and research at Biomatrix led to the discovery of the broad and innovative medical therapeutic uses of elastoviscous solutions of hyaluronan and its derivatives.
She received her BS degree from the University of Florida in 1966, and in 1967 obtained a Master’s degree in biology (endocrine physiology) from Purdue University (West Lafayette, Indiana). She began her research training in 1967 at the Retina Foundation (Boston, MA) where she studied physiology and biochemistry. From 1969 to 1972 she was a Research Associate in the Department of Pharmacology, University of Ottawa, Canada. From 1973 to 1975 she was a Research Associate in the Department of Connective Tissue Research at the Boston Biomedical Research Institute in Boston, MA, where her research on the metabolism of hyaluronan in the eye and joints became the basis for the treatment modality, for the treatment of the symptoms of osteoarthritis. She also worked on the interactions of hyaluronan and other glycosaminoglycans with, and their effects on, inflammatory processes.
In 1975, Dr. Denlinger was appointed Director of the Connective Tissue Research Laboratory in the Eye Research Institute, Department of Ophthalmology, College of Physicians and Surgeons, Columbia University, New York, where she continued her research work and participated in teaching medical students. She also began her studies toward an advanced degree in the Department of Pharmacology at Columbia University.
In 1981, Dr. Denlinger became a staff member of the Connective Tissue Laboratory of the University of Paris VIII. She received a PhD from the Université de Sciences et Techniques in Lille, France, in 1982 for her work on the metabolism of hyaluronan in articular and ocular tissues. Her publications in international scientific journals and books include articles in the areas of ophthalmology, orthopedics, biochemistry and biotechnology.
She also served as Executive Director of the International Society for eye Research, a non-profit international scientific organization that promotes cooperation in eye research activities worldwide, a position she held from 1988 until she stepped down in 1999.